News

Shares of AT&T (NYSE: T) have fallen more than 25% from their 52-week high. Weighing on the telecom giant's stock is concerns about its free cash flow. That has caused some worries that it might not

Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

Long-term shareholders in AT&T (NYSE: T) don't have much to be happy about. Against the backdrop of the S&P 500 index's 166% rally over the last decade, the telecom company's share price has fallen

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and

Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

Shares of AT&T (NYSE: T) were moving higher today as CFO Pascal Desroches made comments at an investor conference reaffirming the company's free-cash-flow guidance and tamped down concerns about the

When investing in equities, even a relatively modest initial sum such as $500 can go a long way, provided investors pick the right stocks and continue adding to their positions regularly. Let's

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the

In the earliest days of the coronavirus vaccine race, Novavax (NASDAQ: NVAX) stood out as a potential winner. As a result, investors bet on the company and drove up its share price more than 2,700%

If you're looking for dividend stocks that can provide steady income and growth potential, you might want to consider adding Amgen (NASDAQ: AMGN) and American Express (NYSE: AXP) to your portfolio

The pandemic isn't over -- much as we might wish it were. An ongoing surge in coronavirus cases is pouring cold water on these hopes. We recently got a stark reminder that the disease spares nobody

Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown

If you're looking for dividend stocks that offer both attractive yields and strong growth prospects, you might want to consider AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Both of

The hot-streak biotech stock of the moment, CymaBay Therapeutics (NASDAQ: CBAY), again rose in price on Tuesday. That extends the company's winning streak on the market following the impressive

Despite its formidable market capitalization of $174 billion and more than 100 years in operation, Abbott Laboratories (NYSE: ABT) is a stock that can sometimes be overlooked. It doesn't make

Biotech stocks are a great way to grow your portfolio over time -- you can get in early on an innovator and benefit as it brings exciting candidates through the pipeline to commercialization. Of